Michela Efficace

707 total citations
11 papers, 487 citations indexed

About

Michela Efficace is a scholar working on Pulmonary and Respiratory Medicine, Cardiology and Cardiovascular Medicine and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Michela Efficace has authored 11 papers receiving a total of 487 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 3 papers in Cardiology and Cardiovascular Medicine and 3 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Michela Efficace's work include Pulmonary Hypertension Research and Treatments (7 papers), Health Systems, Economic Evaluations, Quality of Life (2 papers) and Psoriasis: Treatment and Pathogenesis (2 papers). Michela Efficace is often cited by papers focused on Pulmonary Hypertension Research and Treatments (7 papers), Health Systems, Economic Evaluations, Quality of Life (2 papers) and Psoriasis: Treatment and Pathogenesis (2 papers). Michela Efficace collaborates with scholars based in Switzerland, Italy and France. Michela Efficace's co-authors include Marion Delcroix, Nazzareno Galiè, Kelly Papadakis, Iréne Lang, Adam Torbicki, Diana Bonderman, R. Giorgino, Bruno Degano, Marius M. Hoeper and Kristóf Karlócai and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Journal of the American College of Cardiology.

In The Last Decade

Michela Efficace

9 papers receiving 481 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michela Efficace Switzerland 5 440 368 72 66 50 11 487
Roela Sadushi‐Kolici Austria 14 512 1.2× 409 1.1× 46 0.6× 129 2.0× 33 0.7× 28 606
Sylvia Nikkho Germany 14 559 1.3× 358 1.0× 28 0.4× 93 1.4× 47 0.9× 33 622
R.F. Roscigno United States 8 313 0.7× 216 0.6× 11 0.2× 67 1.0× 31 0.6× 14 359
A. Mañes Italy 2 497 1.1× 364 1.0× 31 0.4× 119 1.8× 48 1.0× 2 518
Beate Enke Germany 8 837 1.9× 590 1.6× 84 1.2× 171 2.6× 80 1.6× 8 898
Mehmet Ata Akıl Türkiye 8 322 0.7× 238 0.6× 45 0.6× 63 1.0× 21 0.4× 16 423
Martha Kingman United States 9 262 0.6× 194 0.5× 19 0.3× 41 0.6× 24 0.5× 21 305
Jason S. Fritz United States 11 466 1.1× 269 0.7× 33 0.5× 64 1.0× 87 1.7× 24 550
J.-L. Jagot France 4 354 0.8× 216 0.6× 17 0.2× 79 1.2× 51 1.0× 8 374
Ignacio Hernández‐González Spain 13 221 0.5× 137 0.4× 40 0.6× 36 0.5× 26 0.5× 42 399

Countries citing papers authored by Michela Efficace

Since Specialization
Citations

This map shows the geographic impact of Michela Efficace's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michela Efficace with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michela Efficace more than expected).

Fields of papers citing papers by Michela Efficace

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michela Efficace. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michela Efficace. The network helps show where Michela Efficace may publish in the future.

Co-authorship network of co-authors of Michela Efficace

This figure shows the co-authorship network connecting the top 25 collaborators of Michela Efficace. A scholar is included among the top collaborators of Michela Efficace based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michela Efficace. Michela Efficace is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Clift, Paul, Felix Berger, Lars Søndergaard, et al.. (2024). Efficacy and safety of macitentan in Fontan-palliated patients: 52-week randomized, placebo-controlled RUBATO Phase 3 trial and open-label extension. Journal of Thoracic and Cardiovascular Surgery. 169(2). 385–394.e5. 2 indexed citations
2.
3.
4.
Mahé, E., et al.. (2023). O09 Long-term safety of ustekinumab in paediatric patients with moderate-to-severe plaque psoriasis: results from an ongoing observational study. British Journal of Dermatology. 189(3). e43–e43. 1 indexed citations
5.
6.
Gatzoulis, Michael Α., Michael J. Landzberg, Maurice Beghetti, et al.. (2018). Evaluation of Macitentan in Patients With Eisenmenger Syndrome. Circulation. 139(1). 51–63. 78 indexed citations
7.
Vachiéry, Jean‐Luc, Marion Delcroix, Hikmet Al‐Hiti, et al.. (2018). Macitentan in pulmonary hypertension due to left ventricular dysfunction. European Respiratory Journal. 51(2). 1701886–1701886. 136 indexed citations
8.
Vachiéry, Jean‐Luc, Marion Delcroix, Hikmet Al‐Hiti, et al.. (2017). MELODY-1: A PILOT STUDY OF MACITENTAN IN PULMONARY HYPERTENSION DUE TO LEFT VENTRICULAR DYSFUNCTION. Journal of the American College of Cardiology. 69(11). 1880–1880. 2 indexed citations
9.
Galiè, Nazzareno, Michael J. Landzberg, Maurice Beghetti, et al.. (2017). P5462Evaluation of macitentan in patients with Eisenmenger syndrome: results from the randomised controlled MAESTRO study. European Heart Journal. 38(suppl_1). 5 indexed citations
10.
Berger, Rolf M.F., Sheila G. Haworth, Damien Bonnet, et al.. (2015). FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion. International Journal of Cardiology. 202. 52–58. 30 indexed citations
11.
Simonneau, Gérald, Adam Torbicki, Marius M. Hoeper, et al.. (2012). Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. European Respiratory Journal. 40(4). 874–880. 230 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Roela Sadushi‐Kolici Breakdown of academic impact, for papers by Sylvia Nikkho Breakdown of academic impact, for papers by R.F. Roscigno Breakdown of academic impact, for papers by A. Mañes Breakdown of academic impact, for papers by Beate Enke Breakdown of academic impact, for papers by Mehmet Ata Akıl Breakdown of academic impact, for papers by Martha Kingman Breakdown of academic impact, for papers by Jason S. Fritz Breakdown of academic impact, for papers by J.-L. Jagot Breakdown of academic impact, for papers by Ignacio Hernández‐González
Rankless by CCL
2026